EPIBONE, INC.
Allogeneic cell-based injectable cartilage regeneration therapy engineered from stem cell-derived building blocks
- Sector
- Biotech
- Headquarters
- NEW YORK, NY
- Latest Form D
- $4.3M, Oct 2025
- Total capital
- $55.7M
- Federal grants
- $5M
- 8 awards · 2015–2025
- Rank in peer group#161 of 514
- Private capital raised
- $47.8M
- 4 Form D · last Oct 2025
- 12 months since last filing
- Federal contracts
- $2.8M
- 5 awards · Defense
- Rank in Biotech#115 of 4373
- Granted patents
- 5
- 16 pending · first 2021
- Rank in peer group#71 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$4.3M
- Federal grantDefense · Phase II · Regenerating Warfighter Mobility With Eb-oc- A Next-generation Living Osteochondral Graft To Treat Combat-acquired Osteoarthritis$1.2M
- Federal contractDefense · Regenerating Warfighter Mobility With Eb-oc- A Next-generation Living Osteochondral Graft To Treat Combat-acquired Osteoarthritis$1.2M
- Federal contractDefense · Next-generation Craniofacial Surgery: Validating Epibone Eb-cmf Regenerative Bone Grafts For Use In The Maxilla$1.2M
- Federal grantDefense · Phase II · Next-generation Craniofacial Surgery: Validating Epibone Eb-cmf Regenerative Bone Grafts For Use In The Maxilla$1.2M
- Federal grantDefense · Phase I · Solution To Provide Cartilage Replacement For Long-term And Progressive Usage$74K
- Federal contractDefense · Solution To Provide Cartilage Replacement For Long-term And Progressive Usage$74K
- Private capital raisedForm D · SEC · 3rd filing$18.5M
- Private capital raisedForm D · SEC · 2nd filing$750K
- Private capital raisedForm D · SEC · 1st filing$24.3M
Show 7 earlier federal awards
- Federal grantDefense · Phase I · Epibone: Solution To Provide Bone Reconstruction Due To Battlefield Injury$75K
- Federal contractDefense · Epibone: Solution To Provide Bone Reconstruction Due To Battlefield Injury$75K
- Federal grantDefense · Phase II · Injectable Off-the-Shelf Cell-Based Therapy Cartilage Filler$1.0M
- Federal contractDefense · Igf::ot::igf. Dha Phase I Proposal H171-009-0021 Titled, "injectable Off-the-shelf Cell-based Therapy Cartilage Filler."$149K
- Federal grantDefense · Phase I · Production and maintenance of tissue-engineered human osteochondral grafts$99K
- Federal grantHealth and Human S · Phase II · Engineered Living Bone Grafts for Complex Craniomaxillofacial Reconstructions$300K
- Federal grantHealth and Human S · Phase II · Engineered Living Bone Grafts for Complex Craniomaxillofacial Reconstructions$999K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
54months
from EPIBONE, INC.’s first federal award to its first private round.
- First federal award · Aug 2015
- Health and Human S · $999K
- First Form D · Feb 2020
- $24.3M · 1st Form D
- Awards before first raise
- 5 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#161 · top 31%
- Granted patents#71 · top 14%
- Linked publications#71 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Sarindr BhumiratanaResearcherExecutive Officer, DirectorLinked by 5 patents · $2.4M in grants as PI
- David ZhuDirectorNamed in SEC Form D filings
- Elma HawkinsDirectorNamed in SEC Form D filings
- Gordana Vunjak-NovakovicDirectorNamed in SEC Form D filings
- Nina TandonExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Robert LangerDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 21- GrantedInjectable Off-the- Shelf Cartilage, Tendon, And Ligament Repair Compositions And Methods Of UseUSPTOUS 12,595,463
- GrantedInjectable Off-the- Shelf Cartilage, Tendon, And Ligament Repair Compositions And Methods Of UseUSPTOUS 12,540,307
- PendingAlternating Pressure And Vacuum System For Decellularizing A Bone MatrixUSPTOApplication 17963304
Show all 21 patent records
- Injectable Off-the- Shelf Cartilage, Tendon, And Ligament Repair Compositions And Methods Of UseApr 7, 2026 · US 12,595,463Granted
- Injectable Off-the- Shelf Cartilage, Tendon, And Ligament Repair Compositions And Methods Of UseFeb 3, 2026 · US 12,540,307Granted
- Alternating Pressure And Vacuum System For Decellularizing A Bone MatrixApr 11, 2024 · Application 17963304Pending
- System And Method For Seeding And CulturingApr 2, 2024 · US 11,946,068Granted
- Systems, Kits, And Devices For Drilling Articular Cartilage And Methods ThereofJul 20, 2023 · Application 17918858Pending
- Porous Polymer Scaffold And Preparation Method ThereofDec 6, 2022 · US 11,517,647Granted
- Graft Transportation And Implantation System And Method For UseJul 14, 2022 · Application 17609843Pending
- Porous Polymer Scaffold And Methods ThereofJun 9, 2022 · Application 17679796Pending
- System And Method For Seeding And CulturingMar 30, 2021 · US 10,961,501Granted
- System And Method For Cell Seeding And CulturingApplication 62483031Pending
- Porous Polymer Scaffold And Preparation Method ThereofApplication PCTUS2017019956Pending
- Alternating Pressure And Vacuum System For Decellularizing A Bone MatrixApplication PCTUS2023034562Pending
- Porous Polymer Scaffold And Preparation Method ThereofApplication 62301280Pending
- Systems, Kits, And Devices For Drilling Articular Cartilage And Methods ThereofApplication PCTUS2021026564Pending
- Graft Transportation And Implantation System And Method Or UseApplication PCTUS2020032008Pending
- Drilling System And MethodApplication 63009576Pending
- Graft Transportation And Implantation System And MethodApplication 62883349Pending
- Graft Transportation And Implantation System And MethodApplication 62846277Pending
- Injectable Off-the- Shelf Cartilage, Tendon, And Ligament Repair Compositions And Methods Of UseApplication PCTUS2019020893Pending
- System And Method For Seeding And CulturingApplication PCTUS2018026730Pending
- Injectable Off-the-shelf Cartilage Repair Compositions And Methods Of UseApplication 62639322Pending
Recent research by its founders
- Tissue-Engineered Osteochondral Allograft Versus Fresh Osteochondral Allograft: Comparable Cartilage and Subchondral Bone Repair in a 14-Month Equine Osteochondral Defect Model20260 cites
- Bioreactors for engineering patient-specific tissue grafts202345 cites
- Microscale strain concentrations in tissue-engineered osteochondral implants are dictated by local compositional thresholds and architecture20234 cites
Related companies, and why
- ARUNA BIO, INC.Similar federal contract value in Biotech · $2.9M in contracts
- STC BIOLOGICS, INCSimilar federal contract value in Biotech · $2.8M in contracts
- SYNVITROBIO, INC.Similar federal contract value in Biotech · $2.8M in contracts
- AGILE SCIENCES, INC.Similar federal contract value in Biotech · $2.7M in contracts
- Amplyx Pharmaceuticals, Inc.Similar federal contract value in Biotech · $2.7M in contracts
- TECHNOVAX INCSimilar federal contract value in Biotech · $2.7M in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .